Oric Pharmaceuticals
ORIC
83 hedge funds and large institutions have $147M invested in Oric Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 20 increasing their positions, 24 reducing their positions, and 40 closing their positions.
158% more call options, than puts
Call options by funds: $2.03M | Put options by funds: $786K
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3.1% less ownership
Funds ownership: 86.27% → 83.18% (-3.1%)
17% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 24
18% less funds holding
Funds holding: 101 → 83 (-18)
19% less capital invested
Capital invested by funds: $182M → $147M (-$34.5M)
38% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$4.32M |
| 2 |
Millennium Management
New York
|
+$4.25M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$3.28M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.66M |
| 5 |
MAM
Monaco Asset Management
Monaco
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$10.4M |
| 2 |
BlackRock
New York
|
-$6.28M |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$3.66M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.93M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.02M |
ORIC Hedge Fund Activity: Q2 2022 in Review
83 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q2 2022, worth a combined $147M — down 19% from $182M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of ORIC and 25 opened new positions — a net loss of 15 holders — while 24 trimmed existing stakes and 20 added.
The largest buyer was Silverarc Capital Management, opening a new position worth an estimated $4.32M. The largest seller was First Manhattan, exiting entirely with an estimated $10.4M sold.
- 83 institutional investors held Oric Pharmaceuticals (ORIC) as of Q2 2022, down from 101 in Q1 2022.
- Funds reported $147M of Oric Pharmaceuticals stock for Q2 2022, down 19% quarter-over-quarter.
- 25 funds opened new Oric Pharmaceuticals positions in Q2 2022 and 40 closed out, a net change of -15 holders.
- The largest Oric Pharmaceuticals buyer in Q2 2022 was Silverarc Capital Management, an estimated $4.32M added.
- The largest Oric Pharmaceuticals seller in Q2 2022 was First Manhattan, an estimated $10.4M sold.
Based on aggregated 13F filings for Q2 2022.